Bessemer Group Inc. Has $237.32 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Bessemer Group Inc. reduced its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 307,412 shares of the company's stock after selling 7,840 shares during the quarter. Bessemer Group Inc.'s holdings in Eli Lilly and Company were worth $237,322,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. CWA Asset Management Group LLC boosted its stake in Eli Lilly and Company by 11.9% during the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after purchasing an additional 724 shares during the period. Centerpoint Advisory Group bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $514,000. M&T Bank Corp boosted its position in shares of Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after buying an additional 1,867 shares during the period. Kentucky Trust Co bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $834,000. Finally, Proficio Capital Partners LLC increased its position in Eli Lilly and Company by 30.2% in the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after acquiring an additional 1,562 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a research report on Friday, January 17th. Finally, Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a report on Monday, February 3rd. Two investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $1,017.67.

Eli Lilly and Company Trading Up 1.5 %

Shares of NYSE LLY traded up $10.71 during mid-day trading on Friday, hitting $731.62. 3,599,692 shares of the company traded hands, compared to its average volume of 3,386,382. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The stock has a market capitalization of $693.70 billion, a price-to-earnings ratio of 62.48, a PEG ratio of 1.40 and a beta of 0.51. The business has a 50 day moving average of $837.05 and a two-hundred day moving average of $822.87.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.